latest news releases from the newsroom
VirtualScopics Reports Fourth Quarter and Year-End 2007 Results
ROCHESTER, N.Y., Feb. 27, 2008 (PRIME NEWSWIRE) -- VirtualScopics, Inc. (Nasdaq:VSCP), leading provider of image-based solutions to the pharmaceutical, biotechnology and medical device industries, today reported record revenues of $5.6 million for the year ended December 31, 2007, compared to $4.7 million for the full-year 2006. Fourth quarter 2007 revenues increased 24%, year over year, to approximately $1.5 million.
W.P. Stewart & Co., Ltd.
W.P. Stewart & Co., Ltd. Reviews Strategic Alternatives
HAMILTON, Bermuda, Feb. 27, 2008 (PRIME NEWSWIRE) -- W.P. Stewart & Co., Ltd. (NYSE:WPL) ("W.P. Stewart" or the "Company") announced today the Board of Directors is reviewing strategic alternatives that could better position it to enhance long-term shareholder value. As part of this effort the Company retained Merrill Lynch in late 2007 as its financial advisor. The Company is currently in discussions with a number of parties; however, there can be no assurances these discussions will result in a successful conclusion. In the coming months the Company will focus on rationalizing its expense base to reflect current market and Company-specific conditions.
XOMA to Present At Susquehanna Financial Group Healthcare Conference On March 4
BERKELEY, Calif., Feb. 27, 2008 (PRIME NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of antibody therapeutics, announced today that Steven Engle, Chairman and Chief Executive Officer of XOMA, is scheduled to present at Susquehanna Financial Group's Second Annual SIGnificant Options in Healthcare Conference. The presentation will take place in New York on Tuesday, March 4, 2008 at 3:00 p.m. Eastern time.
Power Medical Interventions, Inc.
Power Medical Interventions, Inc. Reports 2007 Financial Results
LANGHORNE, Pa., Feb. 27, 2008 (PRIME NEWSWIRE) -- Power Medical Interventions(r), Inc. (Nasdaq:PMII), a leader in developing and commercializing Intelligent Surgical Instruments(tm), today announced financial results for the fourth quarter and twelve months ended December 31, 2007.
Athersys Announces Summary Results for Phase 1 Safety Study of Its Novel Obesity Drug
CLEVELAND, Feb. 27, 2008 (PRIME NEWSWIRE) -- Athersys, Inc. (Nasdaq:ATHX) today announced top-line results from its Phase 1 clinical trial of ATHX-105, its orally administered drug candidate for the treatment of obesity. ATHX-105 was well-absorbed, providing good drug exposures, well-tolerated up to high doses, and had no negative effect on cardiovascular, hematology or other clinical parameters.
Achillion Pharmaceuticals, Inc.
Achillion Reports 2007 Fourth Quarter and Year-End Financial Results
NEW HAVEN, Conn., Feb. 27, 2008 (PRIME NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today reported financial results for the quarter and year ended December 31, 2007.
Universal Detection Technology
Universal Detection Technology Inks Contract to Bring EPA Approved Anti-MRSA Products to Market
LOS ANGELES, Feb. 27, 2008 (PRIME NEWSWIRE) -- Universal Detection Technology (www.udetection.com) (OTCBB:UDTT) (Frankfurt:PO8), a developer of early-warning monitoring technologies to protect people from bioterrorism and other infectious health threats and provider of counter-terrorism consulting and training services, announced today that it has inked a deal to market a line of Anti-Microbial Products approved by the Environmental Protection Agency (EPA). The Product is designed to kill 99.9% of bacteria including Methicillin-resistant Staphylococcus (MRSA), E.coli, Norovirus, and Salmonella.
NASDAQ Announces Mid-month Open Short Interest Positions in NASDAQ Stocks as of Settlement Date February 15, 2008
NEW YORK, Feb. 27, 2008 (PRIME NEWSWIRE) -- At the end of the settlement date of February 15, 2008, short interest in 2,698 NASDAQ Global Market(sm) securities totaled 8,865,941,056 shares compared with 8,441,146,548 shares in 2,707 Global Market issues reported for the prior settlement date of January 31, 2008. The mid-February short interest represents 3.51 days average daily NASDAQ Global Market share volume for the reporting period, compared with 2.94 days for the prior reporting period.